Heart Failure Clinical Trial
— HEAL-CHFOfficial title:
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes. Cellular replacement therapy is a potential approach to repair damaged myocardial tissue, restore cardiac function, which has become a new strategy for the treatment of heart failure. The purpose of this study is to assess the safety, feasibility and efficacy of intramyocardial delivery of cardiomyocytes at the time of coronary artery bypass grafting in patients with chronic heart failure.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | October 30, 2024 |
Est. primary completion date | April 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years to 75 Years |
Eligibility | Inclusion criteria 1. Aged 35-75 (including 35 and 75). 2. Have signed the Informed Consent Form (ICF). 3. Patients have chronic left ventricular dysfunction. 4. Patients have NYHA Class III-IV cardiac function even after improved medication for the treatment of advanced chronic heart failure. 5. Patients have indications for Coronary Artery Bypass Grafting. 6. 20% = LVEF = 45% as determined by echocardiogram (data collected up to 6 months prior to inclusion evaluation are valid; data collected within 1 month since a myocardial infarction are invalid). 7. Weakening or absence of segmental regional wall motion as determined by standard imaging. Exclusion criteria 1. PRA = 20% or DSA-positive. 2. Patient received ICD transplantation, CRT or similar treatment. 3. Patients with valvular heart disease or received heart valvular disease 4. Patients received treatment of percutaneous transluminal coronary intervention (PCI) 5. Patients with atrial fibrillation 6. Patients previously suffered sustained ventricular tachycardia or sudden cardiac death. 7. Baseline glomerular filtration rate <30ml/min/1.73m2. 8. Liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN. 9. Hematological abnormality: A hematocrit <25% as determined by HCT, white blood cell<2500/ul or platelet values <100000/ul without another explanation. 10. Known, serious radiographic contrast allergy, penicillin allergy, streptomycin allergy. 11. Coagulopathy (INR>1.3) not due to a reversible cause. 12. Contra-indication to performance of a MRI scan. 13. Recipients of organ transplant. 14. Clinical history of malignancy within 5 years (patients with prior malignancy must be disease free for 5 years). 15. Non-cardiac condition that limits lifespan <1 year. 16. On chronic therapy with immunosuppressant medication, such as glucocorticoid and TNFa antagonist. 17. Patients allergy to or cannot use immunosuppressant. 18. Serum positive for HIV, HBV, HCV, TP. 19. Currently enrolled other investigational therapeutic or device study. 20. Patients who are pregnant or breast feeding. 21. Other conditions that researchers consider not suitable to participate in this study. |
Country | Name | City | State |
---|---|---|---|
China | HelpThera | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Help Therapeutics | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of sustained ventricular arrhythmias | defined as the proportion of patients experiencing ventricular arrhythmias lasting more than 30 seconds | 1~6 Month Post-operation | |
Primary | Incidence of newly formed tumors | by comparing chest, abdominal and pelvic CT scan and PET-CT scan | 1~6 Month Post-operation | |
Secondary | Overall Left Ventricular systolic performance as assessed by MRI | Size of infracted myocardium, left ventricular side wall thickness at diastolic, interventricular septum thickness, left ventricular ejection fraction, left ventricular end-systolic volume and end-diastolic volume, stroke volume, cardiac output, myocardium density and left ventricular mass at diastolic will be evaluated and compared to baseline values. | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Overall Left Ventricular systolic performance as assessed by Echocardiogram | Interventricular septum thickness at diastolic, left ventricular end-systolic diameter and end-diastolic diameter, left ventricular posterior wall thickness at diastolic, left atrial diameter, left ventricular ejection fraction, mitral flow pattern (E/A) will be evaluated and compared to baseline values. | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Overall Left Ventricular systolic performance as assessed by PET/ECT Scan | Myocardium perfusion | Baseline, 6 and 12 Months Post-operation | |
Secondary | Functional status by 6 minute walk test | Evaluate Functional Capacity via the Six Minute Walk Test | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Functional status by New York Heart Association (NYHA) Classification | Evaluate Functional Capacity via New York Heart Association (NYHA) Class Determination | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Minnesota Living With Heart Failure Questionnaire (MLHFQ) | Evaluate Quality Of Life Changes via Minnesota Living with Heart Failure (MLHF). The Maximum possible scores being 105 and the minimum 0. Higher scores indicate a worse or worsening quality of life, while lower scores or decreasing scores indicate a better quality of life. | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Incidence of Major Adverse Cardiac Events (MACE) | Major Adverse Cardiac Events (MACE), defined as the composite incidence of (1) death, (2) non-lethal myocardial infraction, and (3) hospitalization for worsening HF | Baseline, 1~12 Months Post-operation | |
Secondary | Incidence of Serious Adverse Events (SAE) | SAE justified (all undesirable or unintended diseases or laboratory and imaging disorders and symptoms that occur in subjects after CABG surgery and 12 months postoperative follow-up, or until the subject withdrawals from the study. AE grading will be based on Common Terminology Criteria for Adverse Events (CTCAE) V5.0.) | Baseline, 1~12 Months Post-operation | |
Secondary | Changes in penal reactive antibodies (PRA) | Changes in penal reactive antibodies (PRA) as assessed via blooddraw | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Changes in donor specific antibodies (DSA) | Changes in donor specific antibodies (DSA) as assessed via blooddraw | Baseline, 1, 3, 6 and 12 Months Post-operation | |
Secondary | Incidence of severe arrhythmia | Clinically significant arrhythmias will be recorded by Electrocardiogram monitoring | First month post-operatively | |
Secondary | Changes in cytokines | Change in NT-proBNP as assessed via blooddraw | Baseline,1, 3, 6 and 12 Months Post-operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|